Ann: Patent for Improved Midkine Antibody Allowed in Europe, page-4

Greeted with absolute silence on both the market and the forums (which probably further supports the splitting of the company to allow for really strong announcements of this nature to be recognised in the biotech sphere). I personally think this is tremendous - it wraps in almost complete protection of the midkine assets, and means that if any big pharma is sniffing around (see recent references to Pfizer's involvement in gioblastoma research from @leverage) then there are few if any loopholes to exploit, and they have to pay the piper - which is us!